Stuart Isaacson

7.0k total citations · 2 hit papers
147 papers, 3.3k citations indexed

About

Stuart Isaacson is a scholar working on Neurology, Psychiatry and Mental health and Epidemiology. According to data from OpenAlex, Stuart Isaacson has authored 147 papers receiving a total of 3.3k indexed citations (citations by other indexed papers that have themselves been cited), including 128 papers in Neurology, 24 papers in Psychiatry and Mental health and 18 papers in Epidemiology. Recurrent topics in Stuart Isaacson's work include Parkinson's Disease Mechanisms and Treatments (113 papers), Neurological disorders and treatments (77 papers) and Botulinum Toxin and Related Neurological Disorders (35 papers). Stuart Isaacson is often cited by papers focused on Parkinson's Disease Mechanisms and Treatments (113 papers), Neurological disorders and treatments (77 papers) and Botulinum Toxin and Related Neurological Disorders (35 papers). Stuart Isaacson collaborates with scholars based in United States, United Kingdom and Germany. Stuart Isaacson's co-authors include Robert A. Hauser, Rajesh Pahwa, Clive Ballard, Roger Mills, Hilde Williams, Anne Corbett, Kathy Chi‐Burris, Rohit Dhall, Mark Lew and Jeffrey L. Cummings and has published in prestigious journals such as Proceedings of the National Academy of Sciences, The Lancet and PLoS ONE.

In The Last Decade

Stuart Isaacson

141 papers receiving 3.2k citations

Hit Papers

Pimavanserin for patients with Parkinson's disease psycho... 2013 2026 2017 2021 2013 2017 100 200 300 400
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial
    2013 481 citations Stuart Isaacson et al. profile →
  2. The recommendations of a consensus panel for the screening, diagnosis, and treatment of neurogenic orthostatic hypotension and associated supine hypertension
    2017 268 citations Stuart Isaacson, Mark Lew et al. Journal of Neurology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Stuart Isaacson United States 28 2.3k 830 434 407 379 147 3.3k
Mark Lew United States 29 2.7k 1.2× 1.1k 1.3× 268 0.6× 348 0.9× 450 1.2× 86 3.5k
J.F. Martí-Massó Spain 30 1.8k 0.8× 692 0.8× 131 0.3× 311 0.8× 552 1.5× 146 2.8k
Carlos Singer United States 32 2.8k 1.2× 1.1k 1.3× 134 0.3× 409 1.0× 400 1.1× 134 3.8k
Han Soo Yoo South Korea 30 1.0k 0.4× 352 0.4× 170 0.4× 345 0.8× 507 1.3× 127 2.5k
Padraig O’Suilleabhain United States 25 1.6k 0.7× 654 0.8× 113 0.3× 230 0.6× 165 0.4× 39 2.3k
Florian Wegner Germany 31 1.6k 0.7× 891 1.1× 87 0.2× 202 0.5× 344 0.9× 147 3.1k
George P. Paraskevas Greece 29 1.2k 0.5× 469 0.6× 105 0.2× 638 1.6× 852 2.2× 174 2.8k
Nozomi Hishikawa Japan 29 1.4k 0.6× 709 0.9× 106 0.2× 363 0.9× 847 2.2× 171 3.4k
L. Côté United States 32 2.4k 1.0× 816 1.0× 91 0.2× 489 1.2× 641 1.7× 51 3.5k
Mark Forrest Gordon United States 24 1.7k 0.7× 660 0.8× 74 0.2× 656 1.6× 344 0.9× 83 2.6k

Countries citing papers authored by Stuart Isaacson

Since Specialization
Citations

This map shows the geographic impact of Stuart Isaacson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stuart Isaacson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stuart Isaacson more than expected).

Fields of papers citing papers by Stuart Isaacson

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Stuart Isaacson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stuart Isaacson. The network helps show where Stuart Isaacson may publish in the future.

Co-authorship network of co-authors of Stuart Isaacson

This figure shows the co-authorship network connecting the top 25 collaborators of Stuart Isaacson. A scholar is included among the top collaborators of Stuart Isaacson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Stuart Isaacson. Stuart Isaacson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Aldred, Jason, Tove Henriksen, Martin Bouchard, et al.. (2025). Treatment patterns with long-term foslevodopa/foscarbidopa use in Parkinson’s disease. Parkinsonism & Related Disorders. 134. 107598–107598. 1 indexed citations
2.
Isaacson, Stuart, Richard B. Dewey, Kelly E. Lyons, et al.. (2025). A Pilot Study of AI-Controlled Transcutaneous Peripheral Nerve Stimulation for Essential Tremor. Tremor and Other Hyperkinetic Movements. 15(1). 10–10. 2 indexed citations
3.
Chaudhuri, К. Ray, Manon Bouchard, Rajesh Pahwa, et al.. (2025). Post hoc exploratory analysis of the effect of foslevodopa/foscarbidopa continuous subcutaneous infusion on nocturia in patients with Parkinson’s disease. Clinical Parkinsonism & Related Disorders. 12. 100330–100330.
4.
Ondo, William G., Wen Lv, Yongsheng Hu, et al.. (2025). Transcutaneous Peripheral Nerve Stimulation for Essential Tremor. JAMA Neurology. 82(12). 1235–1235.
5.
Kassubek, Jan, Stewart A. Factor, Johannes Schwarz, et al.. (2024). Long-term safety, tolerability and efficacy of apomorphine sublingual film in patients with Parkinson’s disease complicated by OFF episodes: a phase 3, open-label study. Journal of Neurology. 271(6). 3554–3570. 4 indexed citations
6.
Hauser, Robert A., Alberto J. Espay, Aaron Ellenbogen, et al.. (2023). IPX203 vs Immediate-Release Carbidopa-Levodopa for the Treatment of Motor Fluctuations in Parkinson Disease. JAMA Neurology. 80(10). 1062–1062. 20 indexed citations
7.
Antonini, Angelo, Rajesh Pahwa, Per Odin, et al.. (2022). Psychometric Properties of Clinical Indicators for Identification and Management of Advanced Parkinson’s Disease: Real-World Evidence From G7 Countries. Neurology and Therapy. 11(1). 303–318. 10 indexed citations
8.
9.
Torres‐Yaghi, Yasar, et al.. (2022). Movement Disorder Specialists Survey Regarding Use of Telemedicine During the COVID-19 Pandemic. Telemedicine Journal and e-Health. 28(11). 1651–1657. 1 indexed citations
10.
Isaacson, Stuart, et al.. (2022). Istradefylline for OFF Episodes in Parkinson’s Disease: A US Perspective of Common Clinical Scenarios. PubMed. Volume 12. 97–109. 5 indexed citations
11.
Pahwa, Rajesh, et al.. (2022). Long-term results of carbidopa/levodopa enteral suspension across the day in advanced Parkinson’s disease: Post-hoc analyses from a large 54-week trial. Clinical Parkinsonism & Related Disorders. 8. 100181–100181. 1 indexed citations
12.
13.
Pahwa, Rajesh, Elizabeth Peckham, Winona Tse, et al.. (2020). Symptomatic Relief in Essential Tremor with Home Use of Non-Invasive Neuromodulation Therapy (435). Neurology. 94(15_supplement). 1 indexed citations
14.
Lew, Mark, Robert A. Hauser, Stuart Isaacson, et al.. (2020). Efficacy of Opicapone Compared to Entacapone in Parkinson’s Patients with Motor Fluctuations and ON Hoehn & Yahr ≤ 2.5: A Post Hoc Analysis of BIPARK-1 (4429). Neurology. 94(15_supplement). 1 indexed citations
15.
Fischer, Tanya, Thomas Gasser, Stuart Isaacson, et al.. (2019). Safety, tolerability and pharmacokinetics of oral venglustat in Parkinson’s disease patients with a GBA mutation (S4.002). Neurology. 92(15_supplement). 3 indexed citations
16.
Isaacson, Stuart, Stanley Fahn, Rajesh Pahwa, et al.. (2018). Parkinson's Patients with Dyskinesia Switched from Immediate Release Amantadine to Open‐label ADS‐5102. Movement Disorders Clinical Practice. 5(2). 183–190. 13 indexed citations
17.
Tison, François, Charlotte Keywood, Franck Durif, et al.. (2016). A Phase 2A Trial of the Novel mGluR5‐Negative Allosteric Modulator Dipraglurant for Levodopa‐Induced Dyskinesia in Parkinson's Disease. Movement Disorders. 31(9). 1373–1380. 117 indexed citations
18.
Pahwa, Rajesh, Caroline M. Tanner, Robert A. Hauser, et al.. (2015). Amantadine extended release for levodopa‐induced dyskinesia in Parkinson's disease (EASED Study). Movement Disorders. 30(6). 788–795. 113 indexed citations
19.
20.
Kordek, Radzisław, Paweł P. Liberski, Richard Yanagihara, Stuart Isaacson, & D. C. Gajdusek. (1997). Molecular analysis of prion protein (PrP) and glial fibrillary acidic protein (GFAP) transcripts in experimental Creutzfeldt-Jakob disease in mice. Acta Neurobiologiae Experimentalis. 57(2). 85–90. 16 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Mark Lew Breakdown of academic impact, for papers by J.F. Martí-Massó Breakdown of academic impact, for papers by Carlos Singer Breakdown of academic impact, for papers by Han Soo Yoo Breakdown of academic impact, for papers by Padraig O’Suilleabhain Breakdown of academic impact, for papers by Florian Wegner Breakdown of academic impact, for papers by George P. Paraskevas Breakdown of academic impact, for papers by Nozomi Hishikawa Breakdown of academic impact, for papers by L. Côté Breakdown of academic impact, for papers by Mark Forrest Gordon
Rankless by CCL
2026